Article

Arthritis Foundation's Ease-of-Use Program Identifies Universal Accessibility of Consumer Products and Packaging

Products endorsed by the Arthritis Foundation’s Ease-of-Use Commendation Program are universally accessible, which means that the products don’t have to be specially designed for people with a disability, but they should be designed in way that all consumers can use them.

FOR IMMEDIATE RELEASE

Contact:

Angie Hager

Arthritis Foundation-Rocky Mountain Chapter

2280 S Albion, Denver, CO 80222

303-756-8622

ahager@arthritis.org

November 2009 — Today’s tamper-resistant packaging, child-proof bottles and unwieldy kitchen tools may leave people wondering why companies make “unfriendly” products. All of these products serve a purpose, but many people – especially the 46 million Americans with arthritis – yearn to find easy-to-open medications and household or office supplies that simply make daily tasks less painful and more manageable. The Arthritis Foundation’s Ease-of-Use program encourages manufacturers to design user-friendly products and packing, and nearly 100 products carry the Arthritis Foundation Ease-of-Use Commendation logo.

As the nation’s most common cause of disability, arthritis is an extremely debilitating disease that can affect every aspect of everyday tasks. One in five Americans live each day with the aches and pains of arthritis, which makes even the simplest aspects of life difficult. Arthritis is a disease that affects 46 million adults and nearly 300,000 children. Arthritis is a more frequent cause of activity limitation than heart disease, cancer or diabetes, resulting in more than 19 million people with activity limitations each year.

Products endorsed by the Arthritis Foundation’s Ease-of-Use Commendation Program are universally accessible, which means that the products don’t have to be specially designed for people with a disability, but they should be designed in way that all consumers can use them. Through its Ease-of-Use Program, the Arthritis Foundation recognizes products that meet strict criteria and prove to be easy-to-use.

“Arthritis is a debilitating disease that impacts the lives of millions of Americans,” said Pat Gottfried, president of the Arthritis Foundation, Rocky Mountain Chapter. “The Arthritis Foundation wants those facing these conditions to understand that there are solutions to help.”

All Ease-of-Use products must pass a rigorous evaluation process by experts in universal design at the Georgia Tech Research Institute (GTRI). The scientists conduct tests to determine if the products are easy-to-use for someone with arthritis. In addition, this evaluation includes testing by people living with arthritis.

While the testing process for the commendation involves hands-on testing by people with arthritis, all consumers should find the products easier to use. This universal accessibility is the goal of the Ease-of-Use Program.

Once a product receives a passing evaluation, it then becomes eligible for the program. To date, several products have received the Ease-of-Use Commendation and have been approved to carry the Arthritis Foundation Ease-of-Use Commendation logo.

To learn more about the Ease-of-Use Program or for a complete list of products, visit the Arthritis Foundation Web site at www.arthritis.org.

About Arthritis

Arthritis is the nation’s most common cause of disability with a nationwide economic impact of more than $128 billion annually. The condition strikes all ages and knows no racial or ethnic boundaries. 46 million people have been doctor diagnosed and 300,000 children are affected.

The Arthritis Foundation is the only nationwide, nonprofit health organization helping people take greater control of arthritis by leading efforts to prevent, control and cure arthritis and related diseases — the nation’s most common cause of disability. For more information, contact the Rocky Mountain Chapter, serving Colorado, Montana and Wyoming at 800-475-6447 or online at www.rockymountainarthritis.org

###

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.